Compare Fresenius Kabi Onco. with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ABBOTT INDIA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ABBOTT INDIA FRESENIUS KABI ONCO./
ABBOTT INDIA
 
P/E (TTM) x 22.1 54.8 40.3% View Chart
P/BV x 3.1 13.2 23.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   ABBOTT INDIA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ABBOTT INDIA
Mar-19
FRESENIUS KABI ONCO./
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1768,834 2.0%   
Low Rs795,458 1.4%   
Sales per share (Unadj.) Rs37.71,731.1 2.2%  
Earnings per share (Unadj.) Rs5.1211.9 2.4%  
Cash flow per share (Unadj.) Rs6.7219.9 3.1%  
Dividends per share (Unadj.) Rs065.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs42.5945.2 4.5%  
Shares outstanding (eoy) m158.2321.25 744.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.1 81.8%   
Avg P/E ratio x25.033.7 74.1%  
P/CF ratio (eoy) x18.932.5 58.2%  
Price / Book Value ratio x3.07.6 39.6%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m20,135151,848 13.3%   
No. of employees `0001.23.5 33.1%   
Total wages/salary Rs m7034,356 16.1%   
Avg. sales/employee Rs Th5,176.210,555.5 49.0%   
Avg. wages/employee Rs Th610.41,249.9 48.8%   
Avg. net profit/employee Rs Th699.61,292.2 54.1%   
INCOME DATA
Net Sales Rs m5,96336,786 16.2%  
Other income Rs m181,133 1.6%   
Total revenues Rs m5,98137,919 15.8%   
Gross profit Rs m1,4306,047 23.6%  
Depreciation Rs m258169 152.4%   
Interest Rs m-2623 -115.6%   
Profit before tax Rs m1,2166,989 17.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,485 13.8%   
Profit after tax Rs m8064,503 17.9%  
Gross profit margin %24.016.4 145.9%  
Effective tax rate %28.135.6 79.1%   
Net profit margin %13.512.2 110.4%  
BALANCE SHEET DATA
Current assets Rs m5,10227,610 18.5%   
Current liabilities Rs m2,3858,569 27.8%   
Net working cap to sales %45.651.8 88.0%  
Current ratio x2.13.2 66.4%  
Inventory Days Days15060 249.2%  
Debtors Days Days11327 413.5%  
Net fixed assets Rs m5,1481,057 487.1%   
Share capital Rs m158213 74.4%   
"Free" reserves Rs m6,55619,873 33.0%   
Net worth Rs m6,73220,086 33.5%   
Long term debt Rs m9520-   
Total assets Rs m10,38829,409 35.3%  
Interest coverage x-45.8311.6 -14.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.3 45.9%   
Return on assets %7.515.4 48.8%  
Return on equity %12.022.4 53.4%  
Return on capital %14.634.9 41.8%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,298369 1,435.8%   
Fx outflow Rs m1,7724,918 36.0%   
Net fx Rs m3,525-4,549 -77.5%   
CASH FLOW
From Operations Rs m1,2744,991 25.5%  
From Investments Rs m-1,204-2,570 46.9%  
From Financial Activity Rs m-196-1,428 13.7%  
Net Cashflow Rs m-126993 -12.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 9.6 0.1 9,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   42,599 18,270 233.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   DR. DATSONS LABS  BIOCON   J.B.CHEMICALS  JUBILANT LIFE SCIENCES  AJANTA PHARMA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 172 Points Higher; IT and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours and ended their session near day's high.

Related Views on News

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 0.3% (Market Updates)

Dec 11, 2019 | Updated on Dec 11, 2019

DIVIS LABORATORIES share price has hit an all time high at Rs 1,839 (up 0.5%). The BSE HEALTHCARE Index is up by 0.3%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 0.5%) and SANOFI INDIA (up 0.4%). The top losers include ALKEM LABORATORIES and CAPLIN POINT (down 0.1%).

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS